Research and development is in full swing all over the world, for a viable vaccine to combat the ever growing threat of Coronavirus. Several vaccines have entered the final stages of testing, including the vaccines being developed by Oxford University, Novavax and even Moderna.
India is also developing several vaccines, out of which two have entered human trials.
According to the latest reports, a vaccine will be available by early next year, at the latest. If we are lucky enough, we might see one by the end of this year.
The Serum Institute of India, the world’s largest manufacturer of vaccines by volume, has struck deals with both Oxford University and Novavax to manufacture and supply their vaccine in India and other low-to-moderate-income countries. It said that at least 100 million doses, of potentially billions that it plans to produce, would be made available for as low as Rs. 240, and if possible, lesser, per dose. This low price would be enabled through a new US$ 150 million funding it is receiving from the Bill and Melinda Gates Foundation.
This is a great piece of news, especially since it means that a vaccine would be available to people of all classes, and billions of people can be saved.